Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer

Pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) is a potent stimulator of megakaryocyte colony formation and platelet production. It is likely to be useful in the management of severe thrombocytopenia. To determine its clinical activity and safety, we gave it to...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Lancet (British edition) 1996-11, Vol.348 (9037), p.1279-1281
Hauptverfasser:	Basser, Russell L, Rasko, John EJ, Clarke, Kerrie, Cebon, Jonathan, Green, Michael D, Hussein, Sonay, Alt, Carole, Menchaca, Dora, Tomita, Dianne, Marty, Jenny, Fox, Richard M, Begley, C Glenn
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic agents Biological and medical sciences Blood Body weight Cancer Chemotherapy Dose-Response Relationship, Drug Female Humans Immunotherapy Male Medical research Medical sciences Middle Aged Neoplasm Proteins Neoplasms - blood Pharmacology. Drug treatments Platelet Count - drug effects Polyethylene Glycols Proto-Oncogene Proteins - administration & dosage Proto-Oncogene Proteins - therapeutic use Receptors, Cytokine Receptors, Thrombopoietin Recombinant Proteins - administration & dosage Recombinant Proteins - therapeutic use Therapy Thrombocytopenia - etiology Thrombocytopenia - therapy Thrombopoietin - administration & dosage Thrombopoietin - therapeutic use Toxicity Waring, Fred (1900-84)
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!